- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: January 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in January 2027, from ClinicalTrials.gov.
Trial readouts
166 trials: 73 phase 3 (including phase 2/3) and 93 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Jan 2027 | A. Menarini International Licensing S.A. | –Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With P… | Mixed Dyslipidemia, Hypercholesterolaemia | Phase 3 | Recruiting | NCT07614958 |
| Jan 2027 | AbbVie | UpadacitinibSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan Wit… | Atopic Dermatitis | Phase 3 | Active not recruiting | NCT06701331 |
| Jan 2027 | AbbVie | Livmoniplimab, Budigalimab, Durvalumab and 3 moreA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination W… | Hepatocellular Carcinoma | Phase 2/3 | Active not recruiting | NCT06109272 |
| Jan 2027 | Adneuris Therapeutics, Inc. | Cebranopadol 400 ugAn Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin | Pain | Phase 3 | Recruiting | NCT07845071 |
| Jan 2027 | Akeso | AK117 in combination with AK112A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | NCT06601335 |
| Jan 2027 | Alcon | Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preser…An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults | Ocular Hyperemia | Phase 3 | Recruiting | NCT07578363 |
| Jan 2027 | Biocad | BCD-217, anti-PD1, Excision of the primary lesion and 1 moreA Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | Melanoma Stage III, Melanoma (Skin) | Phase 3 | Active not recruiting | NCT05751928 |
| Jan 2027 | Sino Biopharmaceutical Limited | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclita…A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer | Breast Cancer | Phase 3 | Active not recruiting | NCT06561607 |
| Jan 2027 | Sino Biopharmaceutical Limited | AL2846 CapsulesA Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma | Thyroid Cancer | Phase 3 | Recruiting | NCT06860971 |
| Jan 2027 | Colgate-Palmolive Company | 0.45% SnF HW with NaF (1450 F), 67% Bicarbonate with NaF (1400 F), Colgate Cavity Protection ToothpasteClinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems | Plaque, Dental Plaque and 1 more | Phase 3 | Recruiting | NCT07842991 |
| Jan 2027 | Ems | OMA102Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss | Female Pattern Baldness | Phase 3 | Not yet recruiting | NCT05824065 |
| Jan 2027 | Hyundai Bioscience | CP-COV03A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) | Dengue | Phase 2/3 | Recruiting | NCT07576868 |
| Jan 2027 | Lexicon Pharmaceuticals | SotagliflozinA Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active not recruiting | NCT06481891 |
| Jan 2027 | Praxis Precision Medicines, Inc. | 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeksRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | Focal Epilepsy | Phase 3 | Active not recruiting | NCT07505004 |
| Jan 2027 | QED Therapeutics, a BridgeBio company | infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/dayAn Interventional Study of Infigratinib in Children With Hypochondroplasia | Hypochondroplasia | Phase 2/3 | Enrolling by invitation | NCT06873035 |
| Jan 2027 | Qilu Pharmaceutical Co., Ltd. | QL1206, Prolia®A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | Postmenopausal Women With Osteoporosis at High Risk of Fracture | Phase 3 | Recruiting | NCT07062978 |
| Jan 2027 | Reistone Biopharma Company Limited | RSS0393 ointment 0.03%A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of RSS0393 Ointment… | Plaque Psoriasis Subjects | Phase 3 | Not yet recruiting | NCT07543224 |
| Jan 2027 | Resilience | Resilience PRORandomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only | Cancer | Phase 3 | Recruiting | NCT06867705 |
| Jan 2027 | Shanghai Huilun Pharmaceutical Co., Ltd. | H077 sustained-release tablet, Silodosin capsules Control GroupA Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplas… | Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | Phase 3 | Not yet recruiting | NCT07146386 |
| Jan 2027 | Sinovac Biotech | experimental vaccine, Active Comparator vaccinePhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | Epidemic Meningitis, Meningococcal Vaccines | Phase 3 | Recruiting | NCT07505836 |
| Jan 2027 | Sun Pharmaceutical | Reformulated Levulan Kerastick containing aminolevulinic a…, Blue Light Photodynamic Therapy Illuminator device, BLU-U®…Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities | Actinic Keratosis | Phase 3 | Recruiting | NCT07144852 |
| Jan 2027 | Sun Pharmaceutical | Reformulated Levulan Kerastick containing aminolevulinic a…, Blue Light Photodynamic Therapy Illuminator device, BLU-U®…Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp | Actinic Keratosis | Phase 3 | Recruiting | NCT07144345 |
| Jan 2027 | Telix Pharmaceuticals Limited | 68Ga-PSMA-11PSMA PET Combined With MRI for the Detection of PCa | PCA, Prostate Cancer and 7 more | Phase 3 | Active not recruiting | NCT07052214 |
| Jan 2027 | Ultragenyx Pharmaceutical Inc. | setrusumabSetrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | Osteogenesis Imperfecta | Phase 3 | Active not recruiting | NCT06636071 |
| Jan 2027 | Vantive Health LLC | Prismocitrate 18, PrisMax System Version 3.x with calcium line accessorySafety Evaluation of Prismocitrate 18 in Patients Receiving CRRT | Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT) and 1 more | Phase 3 | Recruiting | NCT05399537 |
| Jan 2027 | Xenon Pharmaceuticals | AzetukalnerAn Open-Label Study of Azetukalner in Major Depressive Disorder | Major Depressive Disorder | Phase 3 | Active not recruiting | NCT06922110 |
| Jan 4, 2027 | AstraZeneca | AZD0780A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH | Heterozygous Familial Hypercholesterolaemia | Phase 3 | Active not recruiting | NCT07000136 |
| Jan 4, 2027 | Merck & Co. | Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan and 4 moreA Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | Phase 3 | Active not recruiting | NCT06356311 |
| Jan 4, 2027 | MoonLake Immunotherapeutics | Sonelokimab, RisankizumabEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Arthritis, Psoriatic | Phase 3 | Active not recruiting | NCT06641089 |
| Jan 5, 2027 | Shanghai Mabgeek Biotech.Co.Ltd | MG-K10 Injection (Humanized Monoclonal Antibody)A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | Dermatitis, Atopic | Phase 3 | Not yet recruiting | NCT07540442 |
| Jan 6, 2027 | AstraZeneca | Anifrolumab (blinded), Anifrolumab (unblinded, open label)Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | Systemic Sclerosis, Scleroderma | Phase 3 | Active not recruiting | NCT05925803 |
| Jan 6, 2027 | Norgine | PLENVU®, Sodium picosulfateA Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparatio… | Bowel Cleansing Prior to Clinical Procedures | Phase 3 | Recruiting | NCT07218523 |
| Jan 7, 2027 | Sanofi | PCV21, 20vPCVStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease | Sickle Cell Disease | Phase 3 | Recruiting | NCT07247188 |
| Jan 8, 2027 | Ocular Therapeutix, Inc | OTX-TKI, AfliberceptStudy to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degen… | Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | NCT06495918 |
| Jan 9, 2027 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | GQ1005, T-DM1A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | HER2-positive Breast Cancer | Phase 3 | Recruiting | NCT07673029 |
| Jan 10, 2027 | Bristol-Myers Squibb | mezigdomide, Pomalidomide, Bortezomib and 1 moreA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participan… | Relapsed or Refractory Multiple Myeloma | Phase 3 | Recruiting | NCT05519085 |
| Jan 11, 2027 | AstraZeneca | AZD0780A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | Cardiovascular Disease | Phase 3 | Active not recruiting | NCT07000123 |
| Jan 11, 2027 | AstraZeneca | Dato-DXd, Osimertinib, Pemetrexed and 2 moreA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in … | Metastatic Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | NCT06417814 |
| Jan 11, 2027 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | M108 monoclonal antibody, Oxaliplatin, CapecitabineM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Adva… | Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | NCT06177041 |
| Jan 12, 2027 | Merck & Co. | Sacituzumab Govitecan, PembrolizumabStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic… | Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | NCT05609968 |
| Jan 13, 2027 | Akeso | AK112, Oxaliplatin, Irinotecan and 2 moreAK112 and Chemotherapy in First-line Metastatic Colorectal Cancer | Colorectal Adenocarcinoma | Phase 3 | Recruiting | NCT06951503 |
| Jan 13, 2027 | AstraZeneca | TezepelumabA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With … | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | NCT06706817 |
| Jan 13, 2027 | iVascular S.L.U. | Angiolite: Sirolimus-eluting stent, Xience: Everolimus-eluting stent, 1-month DAPTIschemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy | Coronary Artery Disease | Phase 3 | Active not recruiting | NCT05952206 |
| Jan 14, 2027 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 608 doseA Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) | Ankylosing Spondylitis | Phase 3 | Recruiting | NCT07261644 |
| Jan 15, 2027 | Sanofi | efanesoctocog alfa (BIVV001)Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | Hemophilia A | Phase 3 | Active not recruiting | NCT04644575 |
| Jan 15, 2027 | IDEAYA Biosciences | IDE196, Crizotinib, Pembrolizumab and 3 moreIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Metastatic Uveal Melanoma | Phase 2/3 | Active not recruiting | NCT05987332 |
| Jan 15, 2027 | Merck & Co. | 9vHPV VaccineEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45… | Papillomavirus Infections | Phase 3 | Active not recruiting | NCT04199689 |
| Jan 18, 2027 | Pfizer | RSVpreFStudy to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. | Lower Respiratory Tract Illness | Phase 3 | Active not recruiting | NCT05035212 |
| Jan 18, 2027 | Takeda Pharmaceutical Company | MaribavirA Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus … | Cytomegalovirus (CMV) | Phase 3 | Recruiting | NCT05319353 |
| Jan 20, 2027 | Turn Therapeutics Inc. | GX-03A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to S… | Eczema Atopic Dermatitis, Eczema and 1 more | Phase 2/3 | Recruiting | NCT07355075 |
| Jan 21, 2027 | Amgen | Maridebart CafraglutideEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Obesity | Phase 3 | Active not recruiting | NCT06858839 |
| Jan 21, 2027 | Amgen | Maridebart cafraglutideEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | Phase 3 | Active not recruiting | NCT06858878 |
| Jan 21, 2027 | TG Therapeutics | UblituximabStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Relapsing Multiple Sclerosis | Phase 3 | Recruiting | NCT05877963 |
| Jan 22, 2027 | Lupin Ltd. | Granular powder in unit dose foil-lined sachet Mexiletine …, Oral Capsule Mexiletine (IR)An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR | Myotonia | Phase 3 | Recruiting | NCT07097701 |
| Jan 25, 2027 | Biotheus Inc. | PM8002, Paclitaxel, TopotecanPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer | SCLC | Phase 3 | Active not recruiting | NCT06616532 |
| Jan 25, 2027 | Novo | Insulin icodec, Insulin glargine, Insulin aspartA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in … | Diabetes Mellitus, Type 1 | Phase 3 | Active not recruiting | NCT07076199 |
| Jan 25, 2027 | Pfizer | RSVpreFA Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF | Respiratory Syncytial Virus (RSV) | Phase 3 | Recruiting | NCT07653100 |
| Jan 25, 2027 | Vertex Pharmaceuticals | SuzetrigineEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathic Pain | Phase 3 | Active not recruiting | NCT06696443 |
| Jan 26, 2027 | GSK | FF/UMEC/VI, ELLIPTA, FF/VIA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Asthma | Phase 3 | Recruiting | NCT05757102 |
| Jan 28, 2027 | Moderna | mRNA-1018-H5A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Influenza | Phase 3 | Active not recruiting | NCT07496450 |
| Jan 28, 2027 | Novartis | Alpelisib, FulvestrantStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast… | Breast Cancer | Phase 3 | Active not recruiting | NCT05038735 |
| Jan 29, 2027 | Novartis | iptacopanStudy of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | C3G | Phase 3 | Recruiting | NCT04817618 |
| Jan 29, 2027 | Novo | ZiltivekimabARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Cardiovascular Risk, Acute Myocardial Infarction (AMI) | Phase 3 | Active not recruiting | NCT06118281 |
| Jan 29, 2027 | Pfizer | disitamab vedotin, pembrolizumab, gemcitabine and 2 moreDisitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | Phase 3 | Active not recruiting | NCT05911295 |
| Jan 30, 2027 | Roche Holding | AfimkibartA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With… | Moderately to Severely Active Ulcerative Colitis | Phase 3 | Active not recruiting | NCT06589986 |
| Jan 30, 2027 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | simmitinib, investigator's choice of chemotherapy,include docetaxel or…A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma | Advanced Oesophageal Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | NCT06656091 |
| Jan 30, 2027 | Sinovac Biotech | Rabies vaccine, Verorab®Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen | Rabies (Healthy Volunteers) | Phase 3 | Not yet recruiting | NCT07055893 |
| Jan 31, 2027 | Johnson & Johnson | Macitentan, Selexipag, Macitentan/Tadalafil FDCA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | Hypertension, Pulmonary | Phase 3 | Recruiting | NCT05179876 |
| Jan 31, 2027 | Merck & Co. | Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes) and 5 moreEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cance… | Urinary Bladder Neoplasms | Phase 3 | Active not recruiting | NCT04241185 |
| Jan 31, 2027 | Ono Pharmaceutical | CenobamateONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. | Epilepsy, Generalized | Phase 3 | Recruiting | NCT06579573 |
| Jan 31, 2027 | Quoin Pharmaceuticals Ltd. | QRX003Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome | Netherton Syndrome | Phase 2/3 | Recruiting | NCT07538583 |
| Jan 31, 2027 | Tiohundra AB | Vasopressin; Methylprednisolone; Hydrocortisone, Sodium chlorideVAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial | Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial | Phase 3 | Recruiting | NCT05139849 |
| Jan 31, 2027 | iRenix Medical, Inc. | IRX-101, Providone-IodineSafety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections | Retinal Disease | Phase 3 | Not yet recruiting | NCT05750589 |
| Jan 2027 | AION Healthspan, Inc. | AION-301A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With P… | Chronic Kidney Disease Stage 3 | Phase 1/2 | Recruiting | NCT06721143 |
| Jan 2027 | Actio Biosciences, Inc. | ABS-1230A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participan… | KCNT1-Related Epilepsy | Phase 2 | Recruiting | NCT07600736 |
| Jan 2027 | Alesta Therapeutics | ALE1A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in … | Hypophosphatasia (HPP) | Phase 1/2 | Recruiting | NCT07179640 |
| Jan 2027 | Arcus Biosciences | Domvanalimab, Quemliclustat, Zimberelimab and 3 moreA Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestin… | Gastrointestinal Tract Malignancies | Phase 2 | Active not recruiting | NCT05329766 |
| Jan 2027 | Aribio Lab Co., Ltd. | Shingrix, CVI-VZV-001Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above | Herpes Zoster | Phase 2 | Not yet recruiting | NCT07481604 |
| Jan 2027 | BicycleTx Limited | BT8009, PembrolizumabStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms and 6 more | Phase 1/2 | Active not recruiting | NCT04561362 |
| Jan 2027 | BioMendics, LLC | 5% TolaSure Topical GelA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex | Epidermolysis Bullosa Simplex | Phase 2 | Recruiting | NCT07027345 |
| Jan 2027 | Biocad | anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high doseStudy of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active … | Ulcerative Colitis (UC) | Phase 2 | Recruiting | NCT07080034 |
| Jan 2027 | CStone Pharmaceuticals | CS2009, Pemetrexed, Carboplatin and 11 moreA Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06741644 |
| Jan 2027 | Caravel Oculus Pty Ltd | Ophthalmic solution (matching formulation without ascorbic…, Ascorbic acid ophthalmic solution 5%A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery | Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery | Phase 2 | Recruiting | NCT07694375 |
| Jan 2027 | Dr. F. Köhler Chemie GmbH | Custodiol-N, CustodiolStudy of Organ Perfusion in Heart Transplantation in Children | Heart Transplantation | Phase 2 | Recruiting | NCT06032195 |
| Jan 2027 | Edgewise Therapeutics, Inc. | Sevasemten Dose 1, Sevasemten Dose 2, Sevasemten Dose 3 and 2 moreA Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) | Duchenne Muscular Dystrophy | Phase 2 | Active not recruiting | NCT05540860 |
| Jan 2027 | Eledon Pharmaceuticals, Inc. | AT-1501Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant | Prevention of Rejection in Kidney Transplant | Phase 1/2 | Recruiting | NCT05027906 |
| Jan 2027 | Evopoint Biosciences Inc. | XNW5004 tabletsTo Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma | Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | Not yet recruiting | NCT06702605 |
| Jan 2027 | EyeD Pharma | TimoD implant, Injector system, Timolol eye drops 0.5%Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery | Glaucoma, Ocular Hypertension | Phase 1/2 | Recruiting | NCT07036510 |
| Jan 2027 | Gilead Sciences | Tilpisertib FosmecarbilStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | Phase 2 | Active not recruiting | NCT06029972 |
| Jan 2027 | Greg Bew | Benzoyl Peroxide 10% BarEvaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option | HSV | Phase 2 | Not yet recruiting | NCT07032649 |
| Jan 2027 | Hanmi Pharmaceutical | HM15275Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus | Obese, Obesity | Phase 2 | Active not recruiting | NCT07205900 |
| Jan 2027 | Hope Biosciences Research Foundation | Autologous HB-adMSCs"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" | Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis | Phase 2 | Active not recruiting | NCT06800404 |
| Jan 2027 | Imvax | IGV-001 Cell Immunotherapy, SOC: TemozolomideA Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma | Glioblastoma | Phase 2 | Active not recruiting | NCT04485949 |
| Jan 2027 | Inflammasome Therapeutics | KamlanoflastKamlanoflast In Amyotrophic Lateral Sclerosis | ALS (Amyotrophic Lateral Sclerosis), ALS and 3 more | Phase 1/2 | Not yet recruiting | NCT07396818 |
| Jan 2027 | Jacobio Pharmaceuticals Co., Ltd. | JAB-30355JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Solid Tumors | Phase 1/2 | Recruiting | NCT06386146 |
| Jan 2027 | Lakewood-Amedex Biotherapeutics Inc. | Antimicrobial agentPhase 2a Dose Finding Study of Nu-3 Gel in Subjects With Mild iDFU | Diabetic Foot Ulcers (DFUs) | Phase 2 | Recruiting | NCT07565506 |
| Jan 2027 | Larimar Therapeutics, Inc. | CTI-1601An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia | Friedreich Ataxia | Phase 2 | Recruiting | NCT06447025 |
| Jan 2027 | Ligachem Biosciences Inc. | LCB84, Anti-PD-1 monoclonal antibodyA Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT05941507 |
| Jan 2027 | Marengo Therapeutics, Inc. | STAR0602, Sacituzumab Govitecan (SG)A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination Wi… | Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1/2 | Recruiting | NCT06827613 |
| Jan 2027 | MediLink Therapeutics (Suzhou) Co., Ltd. | YL201, IvonescimabA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Advanced Solid Tumors, Non Small Cell Lung Cancer and 1 more | Phase 1/2 | Recruiting | NCT07208773 |
| Jan 2027 | Mirum Pharmaceuticals | VolixibatA Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholan… | Primary Biliary Cholangitis, PBC | Phase 2 | Active not recruiting | NCT05050136 |
| Jan 2027 | Newleos Therapeutics, Inc. | NTX-1472A Study of NTX-1472 in Social Anxiety Disorder | Social Anxiety Disorder (SAD) | Phase 2 | Recruiting | NCT07323784 |
| Jan 2027 | OncoVerity, Inc. | Cusatuzumab, Venetoclax, AzacitidineA Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive … | Leukemia, Myeloid, Acute | Phase 2 | Active not recruiting | NCT06384261 |
| Jan 2027 | Prolium Bioscience, Inc | PRO-203A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. | Healthy Volunteers, Systemic Sclerosis (SSc) and 2 more | Phase 1/2 | Recruiting | NCT07641634 |
| Jan 2027 | QBiotics Group Limited | Tigilanol TiglateA Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | Soft Tissue Sarcoma | Phase 2 | Recruiting | NCT05755113 |
| Jan 2027 | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | Meropenem-Vaborbactam, AntibioticsA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infec… | Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Active not recruiting | NCT06672978 |
| Jan 2027 | Sensory Cloud, Inc. | SC0032A Study to Investigate the Efficacy and Safety of SC0032, a Magnesium Salt Oral Spray, in Adults With Refractory or Unexplained Chronic Coug… | Refractory Chronic Cough and Unexplained Chronic Cough | Phase 2 | Recruiting | NCT07690059 |
| Jan 2027 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Hemopfin+Green LightA Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT | Port-wine Birthmarks, Port-Wine Stain and 1 more | Phase 2 | Recruiting | NCT05171894 |
| Jan 2027 | Shanghai Henlius Biotech | –A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection… | Membranous Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | NCT07038382 |
| Jan 2027 | Skyline Therapeutics (US) Inc. | SKG0106Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | Phase 1/2 | Recruiting | NCT05986864 |
| Jan 2027 | Jiangsu Hengrui Medicine | SHR-4375 InjectionA Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT07298772 |
| Jan 2027 | Synendos Therapeutics AG | SYT-510A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder | Generalized Anxiety Disorder | Phase 2 | Recruiting | NCT07478744 |
| Jan 2027 | TenNor Therapeutics Inc. | TNP-2092 for injection, Vancomycin Hydrochloride for Injection (IA), Vancomycin Hydrochloride for Injection (IV) and 2 moreA Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants | Periprosthetic Joint Infection (PJI) | Phase 1/2 | Recruiting | NCT06889701 |
| Jan 2027 | Vaderis Therapeutics AG | VAD044 Part I, VAD044 Part IIAssess Safety and Efficacy of VAD044 in HHT Patients | Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1/2 | Active not recruiting | NCT05406362 |
| Jan 2027 | Zhejiang Teruisi Pharmaceutical Inc. | TRS005A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. | CD20-positive Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | NCT06886139 |
| Jan 2027 | iOnctura | roginolisib, Dostarlimab, DocetaxelA Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) … | Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC | Phase 1/2 | Active not recruiting | NCT06879717 |
| Jan 1, 2027 | Biotheus Inc. | PM8002, FOLFIRIA Study of PM8002 in Combination With Chemotherapy in Patients With NEN | Neuroendocrine Neoplasm | Phase 2 | Active not recruiting | NCT05879055 |
| Jan 1, 2027 | Siga Technologies Inc | Tecovirimat, Smallpox and Mpox VaccineStudy to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS | Smallpox | Phase 2 | Active not recruiting | NCT04957485 |
| Jan 1, 2027 | Second Life Therapeutics | SL-28SL-28 for Advanced Solid Tumours | Head & Neck Cancer, Pancreas Carcinoma and 16 more | Phase 1/2 | Recruiting | NCT07341737 |
| Jan 1, 2027 | Tasly Biopharmaceuticals Co., Ltd. | B1962A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal … | Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | NCT06838546 |
| Jan 3, 2027 | Shenzhen Kangzhe Biotechnology Co., Ltd. | CMS-D002 Capsules 10 mg, CMS-D002 Capsules 25 mg, CMS-D002 Capsules 50 mgPhase II Study of CMS-D002 Capsule for Uterine Fibroids With Menorrhagia | Uterine Fibroids With Menorrhagia | Phase 2 | Recruiting | NCT07402369 |
| Jan 5, 2027 | Hangzhou Sciwind Biosciences Co., Ltd. | ecnoglutide tabletsA Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Part… | Overweight and/or Obesity, Weight Management | Phase 1/2 | Recruiting | NCT07243171 |
| Jan 6, 2027 | Amgen | AMG 732A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | Thyroid Eye Disease | Phase 1/2 | Active not recruiting | NCT06401044 |
| Jan 6, 2027 | Bristol-Myers Squibb | BMS-986470, Famotidine, PantoprazoleA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease | Anemia, Sickle Cell, Healthy Volunteers | Phase 1/2 | Recruiting | NCT06481306 |
| Jan 6, 2027 | Incyte | INCA034176A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD | Chronic Graft-versus-host-disease | Phase 1/2 | Active not recruiting | NCT06843408 |
| Jan 8, 2027 | Sanofi | Isatuximab SC-OBDS, Montelukast, Dexamethasone and 4 moreA Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed … | Plasma Cell Myeloma Refractory | Phase 2 | Recruiting | NCT06356571 |
| Jan 8, 2027 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | XH-S004 20 mg, XH-S004 40 mgA Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-… | Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Active not recruiting | NCT06981091 |
| Jan 11, 2027 | LaNova Medicines Limited | LM101, Toripalimab, RituximabA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors | Malignant Tumors | Phase 1/2 | Recruiting | NCT05615974 |
| Jan 12, 2027 | GSK | Adjuvanted RSVPreF3 vaccineA Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune … | Respiratory Syncytial Virus Infections | Phase 2 | Active not recruiting | NCT07092865 |
| Jan 13, 2027 | Avirmax Biopharma Inc | ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High DoseClinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap… | Neovascular (Wet) AMD | Phase 1/2 | Active not recruiting | NCT06550011 |
| Jan 14, 2027 | Novo | UBT251A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity | Overweight, Obesity | Phase 2 | Recruiting | NCT07395687 |
| Jan 15, 2027 | Biostar Pharma, Inc. | Utidelone, Utidelone in combination with capecitabineA Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Recruiting | NCT06764940 |
| Jan 15, 2027 | Huabo Biopharm Co., Ltd. | HB0025 20 mg/kg plus nab-paclitaxel, HB0025 10 mg/kg plus nab-paclitaxelA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | TNBC | Phase 2 | Enrolling by invitation | NCT07376629 |
| Jan 15, 2027 | XBiotech Inc. | Natrunix 400 mg, Methotrexate (MTX)Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | Rheumatoid Arthritis | Phase 2 | Not yet recruiting | NCT06590090 |
| Jan 16, 2027 | Corbus Pharmaceuticals | CRB-701, Anti-PD-1A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Solid Tumor, Adult | Phase 1/2 | Recruiting | NCT06265727 |
| Jan 18, 2027 | AstraZeneca | Savolitinib, DurvalumabSavolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC | Lung Cancer | Phase 2 | Active not recruiting | NCT05374603 |
| Jan 18, 2027 | Centre for Neuro Skills | Aerobic Exercise (AER), RehabilitationAerobic Exercise After Traumatic Brain Injury | Traumatic Brain Injury | Phase 1/2 | Enrolling by invitation | NCT05786729 |
| Jan 18, 2027 | Sanofi | Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent) and 2 moreStudy of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation i… | Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization | Phase 1/2 | Active not recruiting | NCT06686654 |
| Jan 19, 2027 | Sanofi | SAR445877, Cetuximab, ADG126 and 3 moreA First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors | Solid Tumor | Phase 1/2 | Recruiting | NCT05584670 |
| Jan 20, 2027 | Creative Medical Technology Holdings, INC. | CELZ-201-DDTSafety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain | Chronic Low-back Pain, Degenerative Disc Disease | Phase 1/2 | Active not recruiting | NCT06053242 |
| Jan 21, 2027 | Laboratoires Thea | Slit Lamp Examination, Far Best Corrected Visual Acuity (BCVA), T1695 and 2 moreA Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivi… | Moderate to Severe Vernal Keratoconjunctivitis | Phase 2 | Recruiting | NCT07169695 |
| Jan 23, 2027 | Egle Therapeutics | EGL-001First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors | Solid Tumor, Adult | Phase 1/2 | Recruiting | NCT06622486 |
| Jan 24, 2027 | Chengdu Syncor Pharmaceutical Co., Ltd. | BPR-101 capsules:Investigational product for the treatment…Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients | Bacterial Vaginosis | Phase 2 | Not yet recruiting | NCT07483671 |
| Jan 24, 2027 | Dompé Farmaceutici S.p.A | DFL24498An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease | Dry Eye Disease (DED) | Phase 2 | Recruiting | NCT07503886 |
| Jan 25, 2027 | Novartis | JDQ443, TNO155, tislelizumabStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung and 8 more | Phase 1/2 | Active not recruiting | NCT04699188 |
| Jan 29, 2027 | AstraZeneca | AZD9550, AZD9550 and AZD6234A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obe… | Overweight and Obesity | Phase 1/2 | Active not recruiting | NCT06151964 |
| Jan 29, 2027 | Dynavax Technologies Corp | rF1V-1018Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | Phase 2 | Active not recruiting | NCT07207408 |
| Jan 29, 2027 | IDEAYA Biosciences | IDE196, Binimetinib, CrizotinibStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Metastatic Uveal Melanoma, Cutaneous Melanoma and 2 more | Phase 1/2 | Recruiting | NCT03947385 |
| Jan 29, 2027 | Novartis | QCZ484A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | Hypertension | Phase 2 | Active not recruiting | NCT06857955 |
| Jan 29, 2027 | Novartis | Alpelisib, FulvestrantStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Post… | Breast Neoplasms | Phase 2 | Active not recruiting | NCT04544189 |
| Jan 30, 2027 | Curasight | 64Cu-DOTA-AE105Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer | Prostate Cancer | Phase 2 | Recruiting | NCT06474806 |
| Jan 30, 2027 | Psivac Ltd | Ixovex-1, PembrolizumabIxovex-1 Single Agent and Combination Therapy | Solid Tumor, Head and Neck Cancer | Phase 1/2 | Recruiting | NCT06549946 |
| Jan 30, 2027 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Simmitinib, SG001A Study of Simmitinib Plus SG001 in Advanced Solid Tumors | Advanced Solid Tumor | Phase 1/2 | Not yet recruiting | NCT06132217 |
| Jan 31, 2027 | Creative Medical Technology Holdings, INC. | CELZ-201 Administration, Control GroupSafety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 1/2 | Recruiting | NCT05626712 |
| Jan 31, 2027 | Daiichi Sankyo | DS-5141bLong-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Phase 2 | Active not recruiting | NCT04433234 |
| Jan 31, 2027 | Dermavon Holdings Limited | CMS-D001 50mg, CMS-D001 100mg, CMS-D001 200mgA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult… | Moderate to Severe Atopic Dermatitis | Phase 2 | Not yet recruiting | NCT07465120 |
| Jan 31, 2027 | EXO Biologics S.A. | Endotracheopulmonary Instillation, SuspensionSafety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants | Bronchopulmonary Dysplasia | Phase 1/2 | Recruiting | NCT06279741 |
| Jan 31, 2027 | Grit Biotechnology | GT101 injection, Gemcitabine injectionAutologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer | Adult | Phase 2 | Recruiting | NCT06241781 |
| Jan 31, 2027 | Roche Holding | Obinutuzumab, Glofitamab, Gemcitabine and 1 moreEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma | Phase 2 | Recruiting | NCT06806033 |
| Jan 31, 2027 | Johnson & Johnson | Cetrelimab, AmivantamabA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer | Carcinoma, Non-Small-Cell Lung | Phase 1/2 | Active not recruiting | NCT05908734 |
| Jan 31, 2027 | MediLink Therapeutics (Suzhou) Co., Ltd. | YL202A Study of YL202 in Patients With Advanced Solid Tumors | Non Small Cell Lung Cancer, Colorectal Cancer and 2 more | Phase 2 | Recruiting | NCT07202364 |
| Jan 31, 2027 | Miltenyi Biomedicine GmbH | MB-CART2019.1DALY II Japan/MB-CART2019.1 for DLBCL | DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy | Phase 2 | Recruiting | NCT07288879 |
| Jan 31, 2027 | NeuroBiogen Co., Ltd | KDS2010Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients | Overweight, Obesity and 1 more | Phase 2 | Recruiting | NCT07009171 |
| Jan 31, 2027 | Ono Pharmaceutical | CenobamateSafety of Cenobamate in Japanese Subjects With Partial Onset Seizures | Epilepsies, Partial | Phase 2 | Recruiting | NCT06590896 |
| Jan 31, 2027 | Scancell Ltd | SCIB1 or iSCIB1+ DNA vaccineSCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | Malignant Melanoma, Melanoma (Skin) and 2 more | Phase 2 | Active not recruiting | NCT04079166 |
| Jan 31, 2027 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | SYHA1813, Investigator's Choice TreatmentA Phase II Study of SYHA1813 for Recurrent or Progressive High-Grade Meningioma | Recurrent or Progressive High Grade Meningioma | Phase 2 | Not yet recruiting | NCT06739213 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.